Help Desk

860-305-6955

STRATEGY

A clear roadmap guiding our actions toward impactful and measurable results.

Market Opportunity

The market for opioids is estimated to be $30 billion and growing … But the potential for PPL-138 goes beyond that because many people in the world are in severe pain without access to adequate pain control because of fears of addiction liability. Recent research has demonstrated that PPL-138 also has potential for treatment of addiction as well as for treatment of PTSD, thus expanding the market potential further.

STRATEGIC FOCUS

The strategic objective of the company is to partner with appropriate market leader(s) that have the resources to maximize the market potential of the Phoenix compounds. Several leading pharma companies that have a strategic focus on pain or addiction have indicated interest in partnering by the end of Phase 1. We plan to advance PPL-138 into Phase 1 clinical trials by 2024 and then advance it to Proof of Concept in 2025 in order to position it for optimal deal terms.

Funding

Phoenix has received strong validation of its science from the NIH and the DoD, which together awarded the company grants of more than $12 million to fund the advancement of its compounds. Grant funds have been supplemented with approximately $6 million of private equity investment including a $2 million online public offering of private securities that were oversubscribed under SEC Rule CF. The company is currently applying for additional grants as well as raising funds through private equity investment to fund the further advancement of its compounds.

About Us

Phoenix PharmaLabs welcomes inquiries by organizations seeking a beneficial relationship. Please contact us to explore potential opportunities.

Browse

Articles

Connect
Facebook-f Twitter Instagram

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.